MET-14

MET-14 is an investigational **small-molecule** oncology program from **KOR Life Sciences** designed to inhibit **oxidative phosphorylation** by targeting components of the **electron transport chain**, thereby disrupting tumor bioenergetics and promoting cancer cell death. The program is being developed for **pancreatic ductal adenocarcinoma** and **glioblastoma**, with company materials describing it as an OXPHOS regulator intended to exploit metabolic vulnerabilities in aggressive solid tumors. Based on available pipeline information, MET-14 remains in **preclinical / IND-enabling development** and no clinical-stage data or marketed formulation have been identified.